Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 14, 2026
DataAggregated Company Financials
Companies7
  • 7D-0.6%
  • 3M3.7%
  • 1Y-11.1%
  • YTD-4.5%

Over the last 7 days, the Life Sciences industry has remained flat, although notably Siegfried Holding declined by 6.2%. As for the longer term, the industry has declined 11% in the last year. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 14 Jun 2026CHF 46.6bCHF 10.1bCHF 1.1b35.5x42.7x4.6x
Tue, 12 May 2026CHF 47.3bCHF 10.1bCHF 1.1b38.4x43.4x4.7x
Thu, 09 Apr 2026CHF 47.4bCHF 10.1bCHF 1.1b32.2x41.5x4.7x
Sat, 07 Mar 2026CHF 46.7bCHF 10.1bCHF 1.3b28.4x36.2x4.6x
Mon, 02 Feb 2026CHF 50.3bCHF 10.1bCHF 1.3b33.2x39.5x5x
Wed, 31 Dec 2025CHF 49.3bCHF 10.6bCHF 1.1b29.7x44.9x4.6x
Fri, 28 Nov 2025CHF 49.2bCHF 10.6bCHF 1.1b28.4x44.8x4.6x
Sun, 26 Oct 2025CHF 53.2bCHF 10.6bCHF 1.1b31.4x48.4x5x
Tue, 23 Sep 2025CHF 50.8bCHF 10.6bCHF 1.1b34.1x46x4.8x
Thu, 21 Aug 2025CHF 54.3bCHF 10.7bCHF 1.1b36.2x49x5.1x
Sat, 19 Jul 2025CHF 53.1bCHF 10.1bCHF 1.0b33.2x51.1x5.3x
Mon, 16 Jun 2025CHF 52.9bCHF 10.1bCHF 1.0b32.5x51x5.2x
Wed, 14 May 2025CHF 53.1bCHF 10.1bCHF 1.0b32.6x51.2x5.3x
Fri, 11 Apr 2025CHF 47.7bCHF 10.1bCHF 1.0b27.6x46.4x4.7x
Sun, 09 Mar 2025CHF 53.9bCHF 10.1bCHF 1.0b30.1x51.6x5.3x
Tue, 04 Feb 2025CHF 56.6bCHF 10.1bCHF 1.0b36.1x56.2x5.6x
Thu, 02 Jan 2025CHF 52.7bCHF 10.2bCHF 943.4m35.5x55.8x5.2x
Sat, 30 Nov 2024CHF 53.4bCHF 10.2bCHF 943.7m41x56.6x5.2x
Mon, 28 Oct 2024CHF 56.0bCHF 10.2bCHF 943.5m42x59.4x5.5x
Wed, 25 Sep 2024CHF 55.1bCHF 10.2bCHF 943.3m42.2x58.4x5.4x
Fri, 23 Aug 2024CHF 58.4bCHF 10.2bCHF 920.7m48.2x63.4x5.7x
Sun, 21 Jul 2024CHF 54.0bCHF 10.3bCHF 1.0b46.8x53.9x5.3x
Tue, 18 Jun 2024CHF 50.9bCHF 10.3bCHF 1.0b43.7x50.8x5x
Thu, 16 May 2024CHF 56.3bCHF 10.3bCHF 1.0b46.2x56.2x5.5x
Sat, 13 Apr 2024CHF 55.8bCHF 10.3bCHF 1.0b43.9x55.7x5.4x
Mon, 11 Mar 2024CHF 51.9bCHF 10.2bCHF 995.4m48.1x52.1x5.1x
Wed, 07 Feb 2024CHF 48.0bCHF 10.2bCHF 1.0b41.5x47.1x4.7x
Fri, 05 Jan 2024CHF 41.0bCHF 9.8bCHF 1.5b31.1x27.4x4.2x
Sun, 03 Dec 2023CHF 39.6bCHF 9.8bCHF 1.5b29.4x26.5x4.1x
Tue, 31 Oct 2023CHF 36.4bCHF 9.8bCHF 1.5b25.3x24.4x3.7x
Thu, 28 Sep 2023CHF 45.9bCHF 9.8bCHF 1.5b31.5x30.8x4.7x
Sat, 26 Aug 2023CHF 51.9bCHF 9.8bCHF 1.5b36x34.8x5.3x
Mon, 24 Jul 2023CHF 52.2bCHF 9.8bCHF 1.5b36.1x33.7x5.3x
Wed, 21 Jun 2023CHF 55.6bCHF 9.7bCHF 1.6b35.3x34.1x5.7x
Price to Earnings Ratio

34.1x


Total Market Cap: CHF 55.6bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.7x which is lower than its 3-year average PE of 46.4x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.87%
Healthcare1.86%
Life Sciences-0.63%
Clinical Research and Equipment-0.63%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 490.301.0%
+CHF 328.3m		-13.8%PE37.7x
XLS Xlife SciencesCHF 24.707.4%
+CHF 9.7m		26.7%PS511.6x

Latest News

SKAN
CHF 49.15
SKAN Group
7D
-3.2%
1Y
-33.6%
LONN
CHF 490.30
Lonza Group
7D
1.0%
1Y
-13.8%
BANB
CHF 66.05
Bachem Holding
7D
-3.6%
1Y
21.8%
Narrative Update • Jun 05

BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework

Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.
SFZN
CHF 73.50
Siegfried Holding
7D
-6.2%
1Y
-22.0%
Narrative Update • Jun 01

SFZN: Steady 2026 Guidance And Refined Views Will Support Future Upside

Analysts have modestly raised their average price target on Siegfried Holding by CHF 4 to reflect updated views on valuation, with one firm lifting its target by CHF 4 while another recently adjusted its target down to CHF 96, keeping expectations broadly in line with prior assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the share price, reflected in the CHF 4 upward adjustment.
TECN
CHF 147.50
Tecan Group
7D
-5.8%
1Y
-11.1%
Narrative Update • May 31

TECN: Reduced P/E Expectations Will Limit Perceived Upside Potential

Analysts have trimmed their price targets on Tecan Group by CHF 1 to CHF 10 in recent updates. This reflects revised assumptions around discount rates, profit margins and future P/E expectations.
PPGN
CHF 33.85
PolyPeptide Group
7D
-7.0%
1Y
65.9%
XLS
CHF 24.70
Xlife Sciences
7D
7.4%
1Y
26.7%